Table 3.
Clinical efficiency of refractory cases
| Refractory cases |
Tumor response evaluation1 |
Follow-up period (mo) | Survival2 | |
| Target lesion4 2 mo post-TEA | Time to progress (mo) | |||
| 1 | PR | 6.5 | 8.1 | No |
| 2 | PR | 7.8 | 14.3 | Yes |
| 3 | PR | 4.2 | 7.1 | No |
| 4 | SD | 3.9 | 6.1 | No |
| 5 | SD | 3.7 | 4.9 | No |
| 6 | PR | 6.2 | 10.1 | No |
| 7 | SD | 3.0 | 5.1 | No |
| 8 | PR | 6.5 | 16.7 | Yes |
| 9 | PR | 5.0 | 9.9 | No |
| 10 | PD | 3 | 3.5 | No |
1
RECIST version 1.1;
2
Survival (yes), death (no);
3
Continued to progress;
4
Percentage of response evaluation: CR (0%), PR (60%), SD (30%), PD (10%). TEA: Transarterial embolization ablation; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.